RT Journal Article
SR Electronic
T1 Bovine Colostrum Derived Antibodies Against SARS-CoV-2 Show Great Potential to Serve as a Prophylactic Agent
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.06.08.21258069
DO 10.1101/2021.06.08.21258069
A1 Kangro, Kadri
A1 Kurašin, Mihhail
A1 Gildemann, Kiira
A1 Sankovski, Eve
A1 Žusinaite, Eva
A1 Lello, Laura Sandra
A1 Pert, Raini
A1 Kavak, Ants
A1 Poikalainen, Väino
A1 Lepasalu, Lembit
A1 Kuusk, Marilin
A1 Pau, Robin
A1 Piiskop, Sander
A1 Rom, Siimu
A1 Oltjer, Ruth
A1 Tiirik, Kairi
A1 Kogermann, Karin
A1 Plaas, Mario
A1 Tiirats, Toomas
A1 Aasmäe, Birgit
A1 Plaas, Mihkel
A1 Krinka, Dagni
A1 Talpsep, Ene
A1 Kadaja, Meelis
A1 Gerhold, Joachim M.
A1 Planken, Anu
A1 Tover, Andres
A1 Merits, Andres
A1 Männik, Andres
A1 Ustav, Mart
A1 Ustav, Mart
YR 2021
UL http://medrxiv.org/content/early/2021/07/27/2021.06.08.21258069.abstract
AB Severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) until now imposes a serious burden to health systems globally. Despite worldwide vaccination, social distancing and wearing masks, the spread of the virus is still ongoing. One of the mechanisms how neutralizing antibodies (NAbs) block virus entry into cells encompasses interaction inhibition between the cell surface receptor angiotensin-converting enzyme 2 (ACE2) and the spike (S) protein of SARS-CoV-2. SARS-CoV-2 specific NAb development can be induced in the blood of cattle. Pregnant cows produce NAbs upon immunization, and antibodies move into the colostrum just before calving. Here we immunized cows with SARS-CoV-2 S1 receptor binding domain (RBD) protein in proper adjuvant solutions, followed by one boost with SARS-CoV-2 trimeric S protein, and purified immunoglobulins from colostrum. We demonstrate that this preparation indeed blocks interaction between the trimeric S protein and ACE2 in different in vitro assays. Moreover, we describe the formulation of purified immunoglobulin preparation into a nasal spray. When administered to human subjects, the formulation persists on the nasal mucosa for at least 4 hours as determined by a clinical study. Therefore, we are presenting a solution that shows great potential to serve as a prophylactic agent against SARS-CoV-2 infection as an additional measure to vaccination and wearing masks. Moreover, our technology allows for a rapid and versatile adaption for preparing prophylactic treatments against other diseases by using the defined characteristics of antibody movement into the colostrum.Significance SARS-CoV-2 infections continue to be a high-risk factor for mankind. Antibodies with the potential to neutralize the virus and thus its entry into the host cell have been shown to impose a potent measure against the infection. Human derived neutralizing antibodies are therapeutics and thus fall under the legislation of drugs. However, an alternative could be the purification of efficient neutralizing antibodies from other species. Here, we present immunization of pregnant cows with spike protein of SARS-CoV-2 which results in high quantities of colostrum immunoglobulins that can be easily harvested and safely purified within a remarkably short time. The colostrum immunoglobulin preparation has a great potential to serve in formulations that can be used as prophylactic agent against SARS-CoV-2 infection.Competing Interest StatementThe use of bovine colostrum as a prophylactic agent against SARS-CoV-2 has been patented (US patent application no 63/160,833) by Mario Plaas, K. Kogermann, E. Zusinaite, T. Tiirats, B. Aasmae, A. Kavak, V. Poikalainen, L. Lepasalu, S. Piiskop, S. Rom, R. Oltjer, K. Kangro, E. Sankovski, J. M. Gerhold, R. Pert, A. Mannik, A. Planken, A. Tover, M. Kurasin, M. Ustav and M. Ustav Jr.Clinical TrialTo test the nasal biological availability of the bovine colostrum immunoglobulin preparation a clinical study on 16 healthy volunteers was conducted in accordance with the Declaration of Helsinki and approval was granted by the Tartu University Ethics Committee on March 17th 2021 (approval number 336/T-1). The trial was registered at ClinicalTrials.gov; ClinicalTrials.gov Identifier: NCT04916574Funding StatementThis study was supported by the funding from Enterprise Estonia grant number 2014-2020.4.02.21-0317.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:To test the nasal biological availability of the bovine colostrum immunoglobulin preparation a clinical study on 16 healthy volunteers was conducted in accordance with the Declaration of Helsinki and approval was granted by the Tartu University Ethics Committee on March 17th 2021 (approval number 336/T-1).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData presented in the manuscript will be made available upon contacting the corresponding author. The use of bovine colostrum as a prophylactic agent against SARS-CoV-2 has been patented (US patent application no 63/160,833) by Mario Plaas, K. Kogermann, E. Zusinaite, T. Tiirats, B. Aasmae, A. Kavak, V. Poikalainen, L. Lepasalu, S. Piiskop, S. Rom, R. Oltjer, K. Kangro, E. Sankovski, J. M. Gerhold, R. Pert, A. Mannik, A. Planken, A. Tover, M. Kurashin, M. Ustav and M. Ustav Jr.